(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amgen Pharmaceuticals, cancer research, clinical trial, Dr Lucy Bull Foundation, ICR, ILP, immunotherapy, isolated limb perfusion, Journal for ImmunoTherapy of Cancer, London, Mabs Mardulyn Charitable Foundation, melanoma, NIHR Biomedical Research Centre, oncolytic virus, Professor Alan Melcher, Professor Andrew Hayes, Robert McAlpine Foundation, Royal Marsden Melanoma and Sarcoma Research Fund, sarcoma, Sarcoma UK, T-VEC, talimogene laherparepvec, The Institute of Cancer Research, The Institute of Cancer Research pioneers new dual treatment combining virus therapy and isolated limb perfusion to enhance immune response in advanced cancer, The Royal Marsden NHS Foundation Trust, tumour immunity, United Kingdom, virotherapy
(IN BRIEF) Boehringer Ingelheim and CDR-Life have expanded their partnership through a global licensing agreement to develop CDR111, a trispecific M-gager® antibody designed to reset the immune system by selectively targeting B cells. The collaboration builds upon their prior success … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged antibody-based therapy, Arthritis, autoimmune diseases, B cells, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim and CDR-Life Expand Partnership with New Global Licensing Deal to Advance Autoimmune Disease Therapies, Carine Boustany, CDR-Life, CDR111, Christian Leisner, Geographic Atrophy, global licensing agreement, immune system reset, lupus, multiple sclerosis, pharmaceutical collaboration, T-cell engager, trispecific M-gager, USD 570 million deal, VERDANT Phase 2 trial
(IN BRIEF) The European Investment Bank (EIB) has provided a €20 million loan to Overture Life to develop automated and AI-driven technologies for in vitro fertilization (IVF) and egg freezing. The funding supports the company’s R&D, production expansion, and clinical … Read the full press release
Posted in Artificial Intelligence (AI), Banks, European Union, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Science, Spain, Technology
Tagged AI in healthcare, Bio-Europe 2025, biotechnology, DaVitri platform, EIB, EIB Backs Overture Life’s Innovation to Make IVF More Efficient and Widely Available through AI, EIB Invests €20 Million in Overture Life to Advance AI-Based Fertility and IVF Technologies, European Innovation, European Investment Bank, fertility preservation, fertility technology, Hans Gangeskar, healthcare digitalisation, innovation funding, InvestEU, IVF automation, Karl Nehammer, life sciences, Overture Life, reproductive health, TechEU, Vienna, Women’s Health
(IN BRIEF) The European Medicines Agency (EMA), together with leading European healthcare professional and consumer organisations, has launched the #ItTakesATeam campaign to raise awareness of collective efforts in preventing and managing medicine shortages across the EU. The initiative, co-created with … Read the full press release
Posted in Healthcare, Management, Marketing, Media, News, Pharma & Biotech, United Kingdom
Tagged #ItTakesATeam, awareness campaign, EMA, EMA Unites European Healthcare Partners in #ItTakesATeam Campaign to Tackle Medicine Shortages, Emer Cooke, EU healthcare collaboration, European Association of Hospital Pharmacists, European Association of Nuclear Medicine, European Consumer Organisation, European Medicines Agency, European Paediatric Neurology Society, European Union of General Practitioners, healthcare professionals, Jorge Batista, medicine shortages, medicine supply chain, New EMA Awareness Initiative Highlights Collaborative Efforts Behind Managing Medicine Shortages Across Europe, patient safety, PGEU, public health, regulatory cooperation
(IN BRIEF) Boehringer Ingelheim has licensed a pre-clinical small molecule program from Kyowa Kirin to develop a potential first-in-class therapy for autoimmune diseases, a major global health challenge affecting around 10% of the population. The deal grants Boehringer exclusive worldwide … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged autoimmune diseases, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim Secures Exclusive Global Rights to Develop New Autoimmune Treatment from Kyowa Kirin, Boehringer Ingelheim Strengthens Autoimmune Disease Pipeline with Licensing Agreement from Kyowa Kirin, Carine Boustany, chronic inflammation, drug development, global health, immunology, inflammatory diseases, Kyowa Kirin, licensing agreement, pharmaceutical innovation, pre-clinical program, respiratory diseases, small molecule therapy, Takeyoshi Yamashita
(IN BRIEF) Causeway Therapeutics, a University of Glasgow spin-out, has announced strong Phase 2 results for its novel microRNA therapy, TenoMiR®, used to treat tennis elbow. The study, involving 123 patients across the UK and USA, showed significant improvements in … Read the full press release
Posted in Education, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biotechnology, Causeway Therapeutics, Causeway Therapeutics Advances TenoMiR® Development Following Strong Phase 2 Results, clinical research, Declan Doogan, Derek Gilchrist, Glasgow City Council, Glasgow Riverside Innovation District, Iain McInnes, lateral epicondylitis, microRNA therapy, miR29a, Neal Millar, orthopaedic innovation, phase 2 trial, Phase 3 development, Promising Clinical Data Propel Glasgow Biotech Causeway Therapeutics Toward Full Development of TenoMiR®, Scott Rodeo, Scottish Enterprise, tendinopathy, tendon regeneration, tennis elbow, TenoMiR, University of Glasgow
Pertussis cases surge: Over 60,000 reported in Europe; infants most at risk. Maternal vaccination expands: Finland, Norway, and UK updated pregnancy vaccine strategies. BioNet advances: Submitted recombinant pertussis vaccine to EMA; secured EU-GMP approval. Nasal vaccine progresses: ILiAD’s BPZE1 granted … Read the full press release
Posted in Denmark, European Union, Finland, France, Germany, Healthcare, Ireland, News, Norway, Pharma & Biotech, Science, United Kingdom
Tagged acellular pertussis vaccine, Adacel, antibody avidity, antigen dose, ASEAN, Bio Farma, BioNet, biotechnology, booster dose, Boostrix-IPV, BPZE1, certification, Chulalongkorn University, clinical trial, compliance, Dario Cresci, dTap, ECDC, EMA, EU-GMP, EU-GMP certification, EU/EEA, Europe Confronts Pertussis Resurgence as Infant Cases Rise Amid Falling Immunity and Vaccination Gaps, Europe Faces Pertussis Resurgence Amid Waning Immunity and Falling Maternal Vaccination Rates, European Medicines Agency, European Union, European Union Good Manufacturing Practice, Europe’s Pertussis Vaccine Market Opens to New Entrants as Demand Rises, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, GSK, Hanna Nohynek, health policy, HPRA, human challenge trial, hVIVO, ILiAD Biotechnologies, immunization strategy, infant protection, Innovation Passport, Institut Pasteur, intranasal vaccine, Ireland Health Products Regulatory Authority, Lancet Infectious Diseases, maternal vaccination, MHRA, mucosal immunity, outbreak, pandemic recovery, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Phase 3, Philippe Guillot-Chêne, pregnancy immunization, public health, recombinant pertussis vaccine, recombinant pertussis vaccines, regulatory approval, Sanofi, Tdap, TdaP combination vaccine, V, vaccine, vaccine blunting, vaccine development, Vaccine Hesitancy, vaccine pipeline, vaccine rollout, vaccine shortage, vaccine supply, vaccine uptake, VacPertagen, whooping cough
(IN BRIEF) Fresenius Medical Care will present multiple studies at ASN Kidney Week 2025, highlighting how hemodiafiltration (HDF) enhances clinical outcomes and how artificial intelligence is transforming kidney care. One of the featured oral presentations links HDF to a reduced … Read the full press release
Posted in Artificial Intelligence (AI), Business, Germany, Healthcare, Marketing, Pharma & Biotech, Science, Technology
Tagged AI Chatbot, AI in healthcare, ASN Kidney Week 2025, cardiovascular outcomes, clinical research, dialysis, digital innovation, Frank Maddux, Fresenius Medical Care, Fresenius Medical Care Highlights Real-World Benefits of Hemodiafiltration and AI Innovation at ASN Kidney Week in Houston, HDF, hemodiafiltration, HOUSTON, kidney disease, kidney therapy, nephrology, online high-volume HDF, patient care, precision medicine, Renal Research Institute
BioNet earns EU-GMP certification for its acellular pertussis vaccine, confirming compliance with EU manufacturing and quality standards. Inspection by Ireland’s HPRA supports EMA review of BioNet’s recombinant vaccine candidate VacPertagen. Partnerships expanding: MoU with Indonesia’s Bio Farma to accelerate TdaP … Read the full press release
Posted in European Union, France, Healthcare, Ireland, Pharma & Biotech, Science
Tagged acellular pertussis vaccine, BioNet, BioNet’s EU-GMP Certification Marks Strategic Step Toward EMA Review and Expands Global Vaccine Reach, BioNet’s Manufacturing Accreditation Aligns with Growing International Efforts to Reinforce Pertussis Vaccine Supply, biotechnology, certification, compliance, Dario Cresci, EMA, EU-GMP certification, European Medicines Agency, European Union, European Union Good Manufacturing Practice, From EU-GMP Certification to ASEAN Partnerships BioNet Broadens Its Global Vaccine Strategy, GMP production facilities, HPRA, Ireland Health Products Regulatory Authority, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Philippe Guillot-Chêne, recombinant pertussis vaccines, Regulatory Milestone and Research Progress Signal BioNet’s Expanding Role in Next-Generation Vaccine Development, V, vaccine, VacPertagen
(IN BRIEF) AstraZeneca’s Alexion has secured European Commission approval for Koselugo (selumetinib), the first targeted therapy available to adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The approval is based on the KOMET Phase III trial, … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adult NF1 treatment, Alexion, American Society of Clinical Oncology, APHP, ASCO 2025, AstraZeneca, AstraZeneca Expands Rare Disease Portfolio with EU Approval of Koselugo for Adults with NF1 Tumours, European Commission approval, European Union, Henri Mondor Hospital, Japan approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, Paris East University, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease therapy, selumetinib, The Lancet, tumour response rate, UPEC
(IN BRIEF) BioNet has achieved European Union Good Manufacturing Practice (EU-GMP) certification, a key international standard that validates its facilities and processes for producing high-quality pharmaceuticals. This certification, granted after inspection by Ireland’s Health Products Regulatory Authority (HPRA), allows BioNet … Read the full press release
Posted in European Union, France, Healthcare, Ireland, Pharma & Biotech
Tagged acellular pertussis vaccine, BioNet, biotechnology, certification, compliance, Dario Cresci, EMA, EU-GMP certification, European Medicines Agency, European Union, European Union Good Manufacturing Practice, GMP production facilities, HPRA, Ireland Health Products Regulatory Authority, Pertagen®, pertussis, pertussis vaccine, Pertussis Vaccine Manufacturing, pharmaceutical quality, Philippe Guillot-Chêne, recombinant pertussis vaccines, vaccine, VacPertagen
(IN BRIEF) GSK announced that its B7-H3-targeted antibody-drug conjugate GSK5764227 (GSK’227) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of pulmonary neuroendocrine carcinoma, including small-cell lung cancer (SCLC). The designation is supported … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, cancer research, EMA, EMA Grants Orphan Drug Designation to GSK’s B7-H3 Antibody-Drug Conjugate for Pulmonary Neuroendocrine Carcinoma, FDA, GSK, GSK Strengthens Oncology Pipeline With EMA Orphan Drug Status for GSK’227 in Small-Cell Lung Cancer, GSK5764227, GSK’227, immuno-oncology, lung cancer, NEC, ODD, oncology, oncology pipeline, orphan drug designation, PRIME designation, pulmonary neuroendocrine carcinoma, relapsed or refractory, SCLC, Small cell lung cancer, solid tumours, targeted therapy
(IN BRIEF) GSK has signed an exclusive global licensing agreement with Empirico Inc. for EMP-012, a first-in-class siRNA candidate currently in Phase I trials for chronic obstructive pulmonary disease (COPD). EMP-012 targets a distinct inflammatory pathway, offering potential therapeutic benefit … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biologics, Chronic obstructive pulmonary disease, COPD, drug development, EMP-012, Empirico, gene expression, genetic medicine, GSK, GSK Acquires Global Rights to Empirico’s siRNA Candidate EMP-012 for Chronic Obstructive Pulmonary Disease, GSK and Empirico Partner on First-in-Class siRNA Therapy EMP-012 to Address Unmet Needs in COPD, Healthcare Innovation, inflammation, inflammation pathway, Kaivan Khavandi, licensing agreement, oligonucleotide therapeutics, Omri Gottesman, Phase I clinical trial, precision medicine, respiratory diseases, respiratory pipeline, siRNA, type 2 inflammation
(IN BRIEF) Roche announced that its Phase III INShore trial evaluating Gazyva/Gazyvaro (obinutuzumab) in children and young adults with idiopathic nephrotic syndrome met its primary endpoint, showing superior sustained remission rates at one year compared to mycophenolate mofetil (MMF). The … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged B cell targeting, Basel, Chronic kidney disease, corticosteroids, EMA, FDA, Gazyva, Gazyva/Gazyvaro Demonstrates Superior Sustained Remission in Children and Young Adults With Idiopathic Nephrotic Syndrome, Gazyvaro, idiopathic nephrotic syndrome, immune-mediated kidney diseases, INS, INShore study, Levi Garraway, lupus nephritis, NOBILITY study, obinutuzumab, pediatric nephrology, phase III clinical trial, proteinuria, REGENCY study, renal disease, Roche, Roche Announces Positive Phase III INShore Results for Gazyva/Gazyvaro in Children and Young Adults With Idiopathic Nephrotic Syndrome, sustained remission, targeted therapy
(IN BRIEF) Newcastle University’s Dr Emily Murphy is leading a pioneering project, Sharing Stories for Wellbeing, to explore how creative activities can improve the health and emotional wellbeing of children with long-term medical conditions. With the number of children living … Read the full press release
Posted in Business, Education, Healthcare, Management, News, Science, Society, United Kingdom
Tagged art therapy, child wellbeing, children’s health, clinical psychology, Community Engagement, creative approaches to healthcare, creative health, creative workshops, Dr Emily Murphy, Dr Emily Murphy Leads Newcastle Study on the Role of Creativity in Enhancing Young Patients’ Wellbeing, Great North Museum Hancock, Hatton Gallery, health policy, hospitalised children, long-term conditions, mental health, Newcastle research, Newcastle University, Newcastle University-led Project Sharing Stories for Wellbeing Investigates the Power of Creativity in Enhancing Child Health and Resilience, Paediatric Care, Sharing Stories for Wellbeing, storytelling, wellbeing
(IN BRIEF) Novartis will present new data from 27 abstracts at the 2025 American College of Rheumatology (ACR) Convergence, featuring late-breaking Phase III results from the NEPTUNUS-1 and NEPTUNUS-2 trials of ianalumab in Sjögren’s disease, which could become the first … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged ACR 2025, allergy, Angelika Jahreis, autoimmune diseases, Basel, biologics, biomarker research, CAR-T therapy, Cosentyx, Dermatology, EXPLORE44, Fortitude, HARBOR trial, ianalumab, immunology, NEPTUNUS trials, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Highlights Strong Immunology Pipeline with Positive Phase III Sjögren’s Results and CAR-T Data in Lupus at ACR 2025, Phase III data, psoriatic arthritis, rapcabtagene autoleucel, rheumatology, secukinumab, Sjögren’s disease, small molecules, systemic lupus erythematosus, YTB323
(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, Antibody Oligonucleotide Conjugates, AOCs, Avidity Biosciences, Basel, biopharma, biopharmaceutical innovation, biotechnology, clinical research, DM1, DMD, drug development, Duchenne muscular dystrophy, EXPLORE44 trial, facioscapulohumeral muscular dystrophy, FORTITUDE trial, FSHD, genetic medicine, HARBOR trial, muscle-directed therapy, myotonic dystrophy type 1, neuromuscular diseases, Novartis, Novartis Strengthens Neuroscience Franchise with Acquisition of Avidity Biosciences and Its Muscle-Directed RNA Platform, RNA delivery, RNA therapeutics, San Diego, SpinCo, Vas Narasimhan, xRNA strategy
(IN BRIEF) Evotec SE announced it has received a US$ 25 million payment from Bristol Myers Squibb, marking progress in their joint neuroscience partnership focused on neurodegenerative diseases. The milestone payment will further advance the companies’ preclinical pipeline and research … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged biotechnology, BMS-986419, Bristol-Myers Squibb, clinical trials, Cord Dohrmann, disease-modifying therapies, drug discovery, Evotec and Bristol Myers Squibb Advance Neuroscience Collaboration with New Funding Milestone, Evotec SE, EVT8683, milestone payment, neurodegenerative diseases, neuroscience, neuroscience collaboration, neuroscience research, pharmaceutical innovation, preclinical research, strategic partnership, translational medicine
(IN BRIEF) The EIB and EIF have approved €9.2 billion in financing to boost Europe’s innovation and sustainability agenda, including a landmark €400 million HousingTech initiative to revolutionise the construction industry and enhance affordable housing. The EIF also invested in … Read the full press release
Posted in Banks, Energy, Gas & Oil, Environment, European Union, Financial, Germany, Healthcare, Industrial, Infrastructure & Utilities, Investment, Italy, Lithuania, Luxembourg, Netherlands, News, Poland, Portugal, Real Estate, Technology
Tagged affordable housing, Africa, Brazil, civil society seminar, Clean Industrial Deal, digital transformation, EIB, EIB Group, EIF, EU innovation, European Investment Bank, European Investment Fund, European Union, green transition, Healthcare Innovation, HousingTech, Iceland, Multilateral Development Banks, Nadia Calviño, paediatrics venture capital fund, renewable energy, SERBIA, SMEs, social infrastructure, sustainable housing, sustainable transport, TechEU, UKRAINE, water infrastructure, wind power
(IN BRIEF) Sanofi’s investigational therapy efdoralprin alfa met all primary and key secondary endpoints in the Phase 2 ElevAATe study for alpha-1 antitrypsin deficiency emphysema, demonstrating superior efficacy compared to standard plasma-derived therapy. The results highlight its potential as the … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged AATD emphysema, alpha-1 antitrypsin deficiency, biotechnology, Christopher Corsico, clinical research, David Geffen School of Medicine, efdoralprin alfa, ElevAATe OLE, ElevAATe study, FDA Fast Track, functional AAT, Igor Barjaktarevic, orphan drug designation, phase 2 trial, protein replacement therapy, pulmonary medicine, rare disease, recombinant therapy, respiratory health, respiratory innovation, Sanofi, Sanofi’s Efdoralprin Alfa Shows Superior Results in Phase 2 AATD Emphysema Trial, SAR447537, UCLA
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?